c-Met在结直肠癌中的预后价值：一项荟萃分析。
Prognostic value of c-Met in colorectal cancer: a meta-analysis.
作者信息
Liu Yan, Yu Xiao-Feng, Zou Jian, Luo Zi-Hua
机构信息
Yan Liu, Xiao-Feng Yu, Jian Zou, Zi-Hua Luo, Department of Gastroenterology, Huadong Hospital, Fudan University, Shanghai 200040, China.
出版信息
World J Gastroenterol. 2015 Mar 28;21(12):3706-10. doi: 10.3748/wjg.v21.i12.3706.
Abstract
AIM
To assess the prognostic value of c-Met status in colorectal cancer.
METHODS
We conducted a search in PubMed, Web of Science, and the Cochrane Library covering all published papers up to July 2014. Only studies assessing survival in colorectal cancer by c-Met status were included. This meta-analysis was performed by using STATA11.0.
RESULTS
Ultimately, 11 studies were included in this analysis. Meta-analysis of the hazard ratios (HR) indicated that patients with high c-Met expression have a significantly poorer overall survival (OR) (HR = 1.33, 95%CI: 1.06-1.59) and progression-free survival (PFS) (HR = 1.47, 95%CI: 1.03-1.91). Subgroup analysis showed a significant association between high c-Met expression and poorer overall survival in the hazard ratio reported (HR = 1.41, 95%CI: 1.08-1.74).
CONCLUSION
The present meta-analysis indicated that high c-Met expression was associated with poor prognosis in patients with colorectal cancer.
摘要
目的
评估c-Met状态在结直肠癌中的预后价值。
方法
我们在PubMed、科学网和考克兰图书馆进行了检索，涵盖截至2014年7月发表的所有论文。仅纳入通过c-Met状态评估结直肠癌患者生存情况的研究。本荟萃分析使用STATA11.0进行。
结果
最终，11项研究纳入本分析。对风险比（HR）的荟萃分析表明，c-Met高表达的患者总生存期（OS）显著更差（OR）（HR = 1.33，95%CI：1.06 - 1.59），无进展生存期（PFS）也显著更差（HR = 1.47，95%CI：1.03 - 1.91）。亚组分析显示，在报告的风险比中，c-Met高表达与较差的总生存期之间存在显著关联（HR = 1.41，95%CI：1.08 - 1.74）。
结论
本荟萃分析表明，c-Met高表达与结直肠癌患者的不良预后相关。
相似文献
1
Prognostic value of c-Met in colorectal cancer: a meta-analysis.c-Met在结直肠癌中的预后价值：一项荟萃分析。
World J Gastroenterol. 2015 Mar 28;21(12):3706-10. doi: 10.3748/wjg.v21.i12.3706.
2
High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis.高c-Met表达是结直肠癌的负性预后标志物：一项荟萃分析。
Tumour Biol. 2015 Feb;36(2):515-20. doi: 10.1007/s13277-014-2659-5. Epub 2015 Jan 31.
3
C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis.C-Met作为食管癌鳞状细胞癌和腺癌潜在的新型预后标志物：一项荟萃分析的证据
Panminerva Med. 2017 Mar;59(1):97-106. doi: 10.23736/S0031-0808.16.03228-6. Epub 2016 Sep 16.
4
High expression of anti-apoptotic protein Bcl-2 is a good prognostic factor in colorectal cancer: Result of a meta-analysis.抗凋亡蛋白Bcl-2的高表达是结直肠癌的一个良好预后因素：一项荟萃分析的结果。
World J Gastroenterol. 2017 Jul 21;23(27):5018-5033. doi: 10.3748/wjg.v23.i27.5018.
5
The prognostic value of survivin expression in patients with colorectal carcinoma: a meta-analysis. survivin 表达在结直肠癌患者中的预后价值：一项荟萃分析。
Jpn J Clin Oncol. 2013 Oct;43(10):988-95. doi: 10.1093/jjco/hyt103. Epub 2013 Jul 25.
6
The prognostic value of abnormally expressed lncRNAs in colorectal cancer: A meta-analysis.异常表达的长链非编码RNA在结直肠癌中的预后价值：一项荟萃分析。
PLoS One. 2017 Jun 28;12(6):e0179670. doi: 10.1371/journal.pone.0179670. eCollection 2017.
7
The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer.RON和MET受体共表达在结直肠癌患者中的预后意义。
Dis Colon Rectum. 2008 Aug;51(8):1268-74. doi: 10.1007/s10350-008-9297-1.
8
Prognostic and clinical significance of syndecan-1 in colorectal cancer: a meta-analysis.Syndecan-1在结直肠癌中的预后及临床意义：一项荟萃分析
BMC Gastroenterol. 2015 Oct 30;15:152. doi: 10.1186/s12876-015-0383-2.
9
The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: a systematic meta-analysis.骨桥蛋白对结直肠癌患者预后及临床病理学的影响：一项系统的Meta分析
Sci Rep. 2015 Aug 3;5:12713. doi: 10.1038/srep12713.
10
Lgr5 expression is a valuable prognostic factor for colorectal cancer: evidence from a meta-analysis.Lgr5表达是结直肠癌的一个重要预后因素：一项荟萃分析的证据
BMC Cancer. 2015 Dec 16;15:948. doi: 10.1186/s12885-015-1985-3.
引用本文的文献
1
Targeting the MAP kinase pathway in colorectal cancer: A journey in personalized medicine.靶向结直肠癌中的丝裂原活化蛋白激酶通路：个性化医疗之旅。
Clin Cancer Res. 2025 May 1. doi: 10.1158/1078-0432.CCR-25-0107.
2
Identification of basement membrane-related prognostic model associated with the immune microenvironment and synthetic therapy response in pancreatic cancer: integrated bioinformatics analysis and clinical validation.胰腺癌中与免疫微环境和综合治疗反应相关的基底膜相关预后模型的鉴定：综合生物信息学分析与临床验证
J Cancer. 2024 Oct 14;15(19):6273-6298. doi: 10.7150/jca.100891. eCollection 2024.
3
Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer.间充质-上皮转化因子扩增与结直肠癌不良病理特征及较差临床预后相关。
World J Gastrointest Surg. 2024 May 27;16(5):1395-1406. doi: 10.4240/wjgs.v16.i5.1395.
4
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.TRUSTY 研究中使用血浆血管生成相关因子和游离细胞 DNA 的探索性生物标志物分析：三氟尿苷/替匹嘧啶联合贝伐珠单抗二线治疗转移性结直肠癌的随机、Ⅱ/Ⅲ期研究。
Target Oncol. 2024 Jan;19(1):59-69. doi: 10.1007/s11523-023-01027-8. Epub 2024 Jan 9.
5
A Phase 1 Study of Cabozantinib and Trifluridine/Tipiracil in Metastatic Colorectal Adenocarcinoma.卡博替尼与曲氟尿苷/替匹嘧啶联合用于转移性结直肠癌的1期研究。
Clin Colorectal Cancer. 2024 Mar;23(1):67-72. doi: 10.1016/j.clcc.2023.11.001. Epub 2023 Nov 27.
6
Near-Infrared Imaging of Colonic Adenomas In Vivo Using Orthotopic Human Organoids for Early Cancer Detection.利用原位人器官oids对结肠腺瘤进行近红外体内成像以早期检测癌症
Cancers (Basel). 2023 Sep 29;15(19):4795. doi: 10.3390/cancers15194795.
7
Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer.伊比利亚美洲关于将新生物标志物纳入结直肠癌临床实践的共识综述
Cancers (Basel). 2023 Sep 1;15(17):4373. doi: 10.3390/cancers15174373.
8
Evaluation of [F]AlF-EMP-105 for Molecular Imaging of C-Met.用于C-Met分子成像的[F]AlF-EMP-105评估
Pharmaceutics. 2023 Jul 10;15(7):1915. doi: 10.3390/pharmaceutics15071915.
9
A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01).卡博替尼治疗难治性转移性结直肠癌患者的 II 期研究（AGICC 17CRC01）。
Cancer Res Commun. 2022 Oct 14;2(10):1188-1196. doi: 10.1158/2767-9764.CRC-22-0169. eCollection 2022 Oct.
10
Spatial heterogeneity of cancer associated protein expression in immunohistochemically stained images as an improved prognostic biomarker.免疫组化染色图像中癌症相关蛋白表达的空间异质性作为一种改进的预后生物标志物。
Front Oncol. 2022 Dec 19;12:964716. doi: 10.3389/fonc.2022.964716. eCollection 2022.
本文引用的文献
1
Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.c-MET表达及基因变异状态对结直肠癌肝切除术后患者的临床影响
Cancer Sci. 2014 Aug;105(8):1002-7. doi: 10.1111/cas.12453. Epub 2014 Aug 7.
2
Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.MET 过表达是 KRAS 野生型转移性结直肠癌抗 EGFR 治疗的新预测标志物。
Cancer Chemother Pharmacol. 2014 Apr;73(4):749-57. doi: 10.1007/s00280-014-2401-4. Epub 2014 Feb 6.
3
Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.结直肠癌原发灶及其转移灶中 KRAS 和 PIK3CA 突变、MET 和 PTEN 表达的联合分析。
Mod Pathol. 2013 Feb;26(2):302-13. doi: 10.1038/modpathol.2012.150. Epub 2012 Aug 31.
4
FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk.在结直肠癌的参数中，FAK、CD44v6、c-Met 和 EGFR：肿瘤进展、转移、患者生存和受体串扰。
Int J Colorectal Dis. 2013 Jan;28(1):9-18. doi: 10.1007/s00384-012-1520-9. Epub 2012 Jun 26.
5
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?胰岛素样生长因子 1 受体（IGF1R）和 c-MET 通路在转移性结直肠癌对西妥昔单抗耐药中的作用如何？
Clin Colorectal Cancer. 2011 Dec;10(4):325-32. doi: 10.1016/j.clcc.2011.03.028. Epub 2011 May 11.
6
MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality.MET 在结直肠癌的晚期高度表达，提示预后和死亡率更差。
Anticancer Res. 2009 Nov;29(11):4807-11.
7
The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer.膜性和胞浆性间质表皮生长因子受体（met）的相对分布是I期和II期结肠癌的一个预后指标。
Clin Cancer Res. 2008 Jun 15;14(12):3814-22. doi: 10.1158/1078-0432.CCR-08-0180.
8
The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer.RON和MET受体共表达在结直肠癌患者中的预后意义。
Dis Colon Rectum. 2008 Aug;51(8):1268-74. doi: 10.1007/s10350-008-9297-1.
9
c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases.c-Met基因扩增与晚期结直肠癌及肝转移相关。
Cancer Lett. 2008 Jul 8;265(2):258-69. doi: 10.1016/j.canlet.2008.02.049. Epub 2008 Apr 18.
10
Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome.原发性结肠癌中c-Met癌基因与肝细胞生长因子的分子共表达可预测肿瘤分期及临床预后。
Cancer Lett. 2007 Apr 18;248(2):219-28. doi: 10.1016/j.canlet.2006.07.007. Epub 2006 Sep 1.
Zotero 插件